Triple drug therapy for advanced heart failure with preserved ejection fraction
Part of Heart & circulation clinical trials.
This trial tests a combination of three heart failure drugs (ARNI, SGLT2i, MRA) to see if they improve symptoms and outcomes in people with a type of heart failure where the heart pumps normally but doesn't relax properly (HFpEF).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have heart failure symptoms like shortness of breath or swelling.
- Your heart's squeezing ability is normal (ejection fraction over 50%).
- Your NT-proBNP levels are above a certain threshold (higher if you have atrial fibrillation).
- You have specific signs of heart muscle stiffness or relaxation problems on an echocardiogram.
- You have not taken ARNI, SGLT2i, or MRA drugs for more than 90 days straight in the past year, and have been off them for at least 30 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a heart medicine called ARNI (sacubitril-valsartan) is safe and works well for people who have a durable LVAD and moderate-to-severe heart pumping weakness. It may help improve symptoms and outcomes, while carefully checking side effects in this higher-risk group.
This trial tests whether combining exercise with a medication that blocks a protein called activin can reduce inflammation, improve heart function, and help with thinking in people with heart failure with preserved ejection fraction (HFpEF).
This trial tests an investigational drug for people with a type of heart failure where the heart pumps normally but is stiff. The goal is to see if the drug can improve symptoms and quality of life.
This trial tests a new, faster way to increase heart failure medications during a hospital stay, aiming to get patients on the right doses sooner. It is for people with weak heart pumping (ejection fraction 40% or less) who are currently in the hospital for heart failure and are on low doses of standard medications.
This study tests whether a combination of two drugs usually used for heart failure or diabetes can reduce thickening and scarring of the heart muscle in people with severe aortic stenosis after their valve is replaced. The goal is to help the heart recover more fully after the procedure.
This study tests whether a medication called sacubitril/valsartan can improve the heart's ability to relax and fill with blood (diastolic function) in people with heart failure with reduced ejection fraction. It may help improve your heart function and overall well-being.
Hear when a new HFpEF trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.